OS Therapies Incorporated (NYSEAMERICAN:OSTX) Sees Large Growth in Short Interest

OS Therapies Incorporated (NYSEAMERICAN:OSTX) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totaling 389,268 shares, a growth of 82.1% from the November 30th total of 213,747 shares. Based on an average trading volume of 533,104 shares, the short-interest ratio is currently 0.7 days. Currently, 1.2% of the company’s stock are short sold. Currently, 1.2% of the company’s stock are short sold. Based on an average trading volume of 533,104 shares, the short-interest ratio is currently 0.7 days.

Institutional Investors Weigh In On OS Therapies

Institutional investors have recently made changes to their positions in the company. Susquehanna International Group LLP bought a new position in OS Therapies during the 3rd quarter worth $29,000. Mercer Global Advisors Inc. ADV acquired a new stake in OS Therapies during the third quarter worth approximately $40,000. Ground Swell Capital LLC bought a new position in OS Therapies during the 3rd quarter worth $40,000. Bridgeway Capital Management LLC acquired a new position in OS Therapies in the 2nd quarter valued at $47,000. Finally, XTX Topco Ltd acquired a new stake in shares of OS Therapies during the 2nd quarter worth $63,000.

OS Therapies Stock Down 2.0%

Shares of OSTX stock traded down $0.03 during trading on Monday, reaching $1.48. 251,339 shares of the company’s stock were exchanged, compared to its average volume of 444,485. OS Therapies has a twelve month low of $1.12 and a twelve month high of $7.00. The firm’s fifty day moving average price is $1.77 and its 200-day moving average price is $1.89. The stock has a market capitalization of $52.11 million, a PE ratio of -1.80 and a beta of -4.01.

OS Therapies (NYSEAMERICAN:OSTX) last released its quarterly earnings data on Friday, November 14th. The company reported ($0.21) EPS for the quarter. As a group, analysts anticipate that OS Therapies will post -0.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

OSTX has been the topic of several recent analyst reports. D. Boral Capital reaffirmed a “buy” rating and set a $20.00 price target on shares of OS Therapies in a research report on Monday, December 15th. Zacks Research raised shares of OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Finally, Lake Street Capital dropped their price target on shares of OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a research report on Tuesday, November 18th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, OS Therapies presently has a consensus rating of “Moderate Buy” and a consensus price target of $17.33.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.